

ASX / MEDIA RELEASE

18 NOVEMBER 2019

Cochlear advises of FDA clearance for the Cochlear™ Osia® 2 System

Sydney, 18 November 2019 (ASX:COH): Cochlear Limited today advises it has received FDA clearance for the Cochlear™ Osia® 2 System. The system is indicated and approved in the US for adults and children (12 years and older) with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness.

The Osia 2 System is the world's first active osseointegrated steady-state implant, using digital piezoelectric stimulation to bypass damaged areas of the natural hearing system and send sound vibrations directly to the cochlea.

Cochlear will commence the commercial rollout of the Osia 2 System in the US during the second half of FY20. Availability in other countries will be subject to regulatory approvals.

For further information, please contact:

Analysts

Kristina Devon
Head of Investor Relations
Email: kdevon@cochlear.com
Ph: + 61 2 9611 6691

Media

Jennifer Stevenson
Head of Corporate Communications
Email: jstevenson@cochlear.com
Ph: +61 2 9611 6959